![]() We have developed a comprehensive set of experimental tools that allows us to fully decode the immune synapse. ![]() Further, DECODE is a powerful platform that allows a unique and in-depth understanding of cellular immune responses, and that knowledge is critical for developing the next generation of cellular-based vaccines in society’s long-term fight against the global public health threat of SARS-CoV-2. ![]() Understanding T cell engagement at the precise epitope level should guide the development of novel therapeutic approaches beyond applications to SARS-CoV-2. Our SARS-CoV-2 research provides insights into how the immune system responds to this infection and suggests mechanisms by which emerging virus variants could escape T cell recognition. The value of decoding the immune synapse is that understanding the antigen and T cell or T cell component that matters, allows us to look across patient populations and create new immune medicines across disease categories. In fact, we are in clinical-stage research in cancer, and have done the same kind of work in type 1 diabetes. Explain how this technology platform to make discoveries in cancer, autoimmunity, and other infectious diseases.Ĭoyle: SARS-CoV-2 isn’t the first disease where we used the DECODE platform. Using our proprietary technology discovers disease-causing antigens as well as the T cells that recognize those antigens, Repertoire scientists identified specific viral epitopes from SARS-CoV-2 that were recognized by both CD4+ and CD8+ T cells and described how individuals present these epitopes based on their genetic backgrounds and the expression of their unique human leukocyte antigens (HLA) haplotypes. However, it is unknown whether humoral immunity induced by these vaccines will lead to long-term protection or adequate coverage of emerging viral variants. Repertoire scientists created and developed the DECODE suite of technologies, which allow in-depth characterization of TCR-antigen pairs, and the ability to rationally design and develop novel targeted immune medicines.Įxplain the company’s DECODE platform and the role it played in the T cell recognition of SARS-CoV-2.Ĭoyle: Current vaccines are primarily designed to induce antibody responses to the spike protein of SARS-CoV-2. We are founded on the belief that the repertoire of TCR-antigen codes that drive health and disease represents one of the greatest opportunities for innovation in medical science. Tell us about Repertoire Immune Medicines.Ĭoyle: Repertoire Immune Medicines is a clinical-stage biotechnology company working to unlock and direct the power of the human immune system to prevent or treat cancer, as well as autoimmune and infectious disease. I caught up with Anthony Coyle, Ph.D., President, Research and Development at Repertoire Immune Medicines to learn more about Repertoire’s DECODE platform and the role it played in the T cell recognition of SARS-CoV-2. This research indicates how SARS-CoV-2 variants may avoid immune surveillance and informs the design of new T cell-based vaccines that can provide long term immunity. By Erin Harris, Editor-In-Chief, Cell & Geneįollow Me On Twitter Immune Medicines, a clinical-stage biotech company creating a new category of immune therapies for cancer, autoimmunity, and infectious disease, recently announced pre-published data revealing new insights into T cell recognition of SARS-CoV-2.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |